Disability progression in relapsing MS tends to follow one of four distinct patterns, according to a new study.

A single dose of Immutep’s MS therapy, IMP761, was well tolerated and reduced T-cell activity for up to 23 days in healthy ...

People with higher blood levels of certain manufactured compounds that persist in the environment are more likely to be ...

Fear of relapse and worsening disease is common for MS patients, leading to poorer mental health, per a study calling for ...

The CEMIP enzyme inhibits the growth of oligodendrocytes and may serve as a therapeutic target to boost myelin repair in MS, ...

A clinical trial testing whether music therapy can make botulinum toxin injections for spasticity more comfortable is ...

MS relapses are more common in spring and summer, coinciding with warmer, drier weather and atmospheric changes, a study ...

Taking lipoic acid failed to ease progressive MS symptoms in a clinical trial, but the antioxidant showed signs of slowing ...

Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

Gadoquatrane showed pediatric safety and pharmacokinetic profiles similar to adults in a study, supporting use as a low-dose ...

A new analysis found that eating both oily fish and wholemeal/wholegrain bread may help lower one's risk of developing ...

Disease-modifying therapies for MS that prevent brain volume loss are linked to reduced long-term disability, new data show.